A/Prof Michael Chao

  • MBBS, FRANZCR, DMedSci
  • Radiation Oncologist
  • Spoken languages English, Cantonese

Overview

Special clinical interests in Breast, Urology, Stereotactic Radiation Therapy, Brachytherapy and Rectal Spacers

Michael is an Associate Professor and Radiation Oncologist specialising in breast, lung and prostate cancers.

He has over 21 years of experience as a radiation oncologist. His particular area of expertise is in prostate brachytherapy (which includes both Iodine-125 low dose rate (LDR) permanent seed implants and Iridium-192 high dose rate (HDR) temporary implants) and rectal spacers for prostate cancer which he introduced in 2013. He has now completed more than 1000 prostate cancer implants and more than 500 rectal spacer procedures. In addition, he has a major interest in the use of preoperative radiotherapy for locally advanced breast cancers prior to breast reconstructions and also for early disease where he is leading innovative partial breast treatments.

Michael completed his MBBS at Monash University in 1991 graduating with Honours. He received his Fellowship of the Royal Australian and New Zealand College of Radiologists (FRANZCR) in 1999. This was followed by two years as a research fellow at the DNA Research Laboratory at the Peter MacCallum Cancer Centre. He was both an NHMRC Scholar and Sir Edward ‘Weary’ Dunlop Research Fellow. He has also completed his doctorate (DMedSc) with the University of Melbourne via the Department of Surgery. He commenced as a consultant radiation oncologist in 2000 joining Genesis Care Victoria. He consults at the Ringwood and Frankston Genesis Care Radiation Oncology Centres. He is both an honorary radiation oncologist Maroondah Hospital (Eastern Health) and A/Prof at the Olivia Newton John Cancer and Wellness Centre where he is the breast cancer lead.

Awards received

  • Jean C Tolhurst
  • NHMRC Scholar

Research interests

  • Preoperative breast RT for facilitation of one stage mastectomy and breast reconstruction
  • Rectal spacing for prostate radiation therapy
  • Stereotactic prostate radiation therapy

Publications and affiliations

  • Quality of life after breast conserving therapy and adjuvant radiotherapy for non low risk ductal carcinoma insitu (BIG3-07/TROG 07.01): 2 year results of a randomised controlled phase 3 trial. King M, Link E, Whelan T, Olivotto I, Kunkler I, Westenberg A, Gruber G, Schofield P, Chua BH and BIG 3-07/TROG 07.01 trial investigators. Lancet Oncol. 2020; 21(5): 685-698.
  • Vertebral fractures following stereotactic body radiotherapy for spine metastases. Abbouchie H, Chao M, Tacey M, Wasiak J, Lim Joon D, Ho H, Guerrieri M, Ng M, Foroudi F. J Med Imaging Radiat Oncol. 2020; 64(2): 293-302.
  • Vertebral fractures following stereotactic body radiotherapy for spine oligometastasis: a multi-institutional analysis of patient outcomes. Abbouchie H, Chao M, Tacey M, Wasiak J, Lim Joon D, Ho H, Guerrieri M, Ng M, Foroudi F. Clin Oncol. 2020; 32(7): 433-441.
  • Assessment of intrafraction motion of the urinary bladder using magnetic resonance imaging (cineMRI). Wilson C, Moseshvili E, Tacey M, Quin I, Lawrentschuk N, Bolton D, Lim Joon D, Chao M, Dunshea T, Kron T, Foroudi F. Clin Oncol. 2020; 32(2): 101-109.
  • PSMA PET/CT guided stereotactic ablative body radiotherapy (SABR) for recurrent oligometastatic prostate cancer. Ong WL, Lim Joon D, Chao M, Farrugia B, Khoo V, Lawrentschuk N, Bolton D, Foroudi F. BJU Int. 2019; 124(S1): 19-30.

Professional memberships

  • American Society of Therapeutic Radiology & Oncology
  • European Society of Radiation Oncology
  • Australasian Society of Breast Diseases
  • American Brachytherapy Society
  • Australasian Brachytherapy Group